Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors

Eduardo A. Perez, Alan S. Livingstone, Dido Franceschi, Caio Rocha-Lima, David J. Lee, Nicole Hodgson, Merce Jorda, Leonidas G. Koniaris

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

BACKGROUND: Gastrointestinal stromal tumors (GISTs) have been recognized as the most common mesenchymal tumors of the gastrointestinal tract. The most effective treatment for unresectable tumors is imatinib mesylate, based on two phase II trials. Because no phase III clinical trial has been undertaken, we sought to determine both current population-based incidence and whether improved outcomes noted in both individual centers and clinical trials have also been observed in a large prospective cancer registry earlier and after the introduction of imatinib. STUDY DESIGN: The 13-center cumulative tumor registry (April 2005 release) from the Surveillance, Epidemiology, and End Results (SEER) database was queried from 1992 to 2002 to determine incidence and associated outcomes for patients diagnosed with GIST. Confirmations of incidence trends using the incident Florida Cancer Data System (FCDS, 2005 release) were also determined. RESULTS: A 25-fold age-adjusted increase in incidence of GIST, from 0.028 per 100,000 in 1992 to 0.688 per 100,000 in 2002, was observed. This increase is mostly because smooth-muscle tumors have been reclassified as GISTs, but it also represents a 50% increase in population- and age-adjusted gastrointestinal mesenchymal tumor diagnosis since 1992. Despite rising GIST incidence rates, there has been a marked improvement in survival since 2000, coinciding with the introduction of the tyrosine kinase inhibitor imatinib into clinical practice. CONCLUSIONS: The diagnosis of GIST has dramatically increased since 1992. Survivals have greatly improved since 2000, when imatinib mesylate was FDA approved.

Original languageEnglish (US)
Pages (from-to)623-629
Number of pages7
JournalJournal of the American College of Surgeons
Volume202
Issue number4
DOIs
StatePublished - Apr 1 2006

Fingerprint

Gastrointestinal Stromal Tumors
Incidence
Neoplasms
Registries
Smooth Muscle Tumor
Phase III Clinical Trials
Survival
Information Systems
Protein-Tyrosine Kinases
Population
Gastrointestinal Tract
Epidemiology
Clinical Trials
Databases
Imatinib Mesylate

ASJC Scopus subject areas

  • Surgery

Cite this

Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. / Perez, Eduardo A.; Livingstone, Alan S.; Franceschi, Dido; Rocha-Lima, Caio; Lee, David J.; Hodgson, Nicole; Jorda, Merce; Koniaris, Leonidas G.

In: Journal of the American College of Surgeons, Vol. 202, No. 4, 01.04.2006, p. 623-629.

Research output: Contribution to journalArticle

Perez, Eduardo A. ; Livingstone, Alan S. ; Franceschi, Dido ; Rocha-Lima, Caio ; Lee, David J. ; Hodgson, Nicole ; Jorda, Merce ; Koniaris, Leonidas G. / Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. In: Journal of the American College of Surgeons. 2006 ; Vol. 202, No. 4. pp. 623-629.
@article{6adfd13282ae449fa7f4f181240184ad,
title = "Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors",
abstract = "BACKGROUND: Gastrointestinal stromal tumors (GISTs) have been recognized as the most common mesenchymal tumors of the gastrointestinal tract. The most effective treatment for unresectable tumors is imatinib mesylate, based on two phase II trials. Because no phase III clinical trial has been undertaken, we sought to determine both current population-based incidence and whether improved outcomes noted in both individual centers and clinical trials have also been observed in a large prospective cancer registry earlier and after the introduction of imatinib. STUDY DESIGN: The 13-center cumulative tumor registry (April 2005 release) from the Surveillance, Epidemiology, and End Results (SEER) database was queried from 1992 to 2002 to determine incidence and associated outcomes for patients diagnosed with GIST. Confirmations of incidence trends using the incident Florida Cancer Data System (FCDS, 2005 release) were also determined. RESULTS: A 25-fold age-adjusted increase in incidence of GIST, from 0.028 per 100,000 in 1992 to 0.688 per 100,000 in 2002, was observed. This increase is mostly because smooth-muscle tumors have been reclassified as GISTs, but it also represents a 50{\%} increase in population- and age-adjusted gastrointestinal mesenchymal tumor diagnosis since 1992. Despite rising GIST incidence rates, there has been a marked improvement in survival since 2000, coinciding with the introduction of the tyrosine kinase inhibitor imatinib into clinical practice. CONCLUSIONS: The diagnosis of GIST has dramatically increased since 1992. Survivals have greatly improved since 2000, when imatinib mesylate was FDA approved.",
author = "Perez, {Eduardo A.} and Livingstone, {Alan S.} and Dido Franceschi and Caio Rocha-Lima and Lee, {David J.} and Nicole Hodgson and Merce Jorda and Koniaris, {Leonidas G.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1016/j.jamcollsurg.2006.01.002",
language = "English (US)",
volume = "202",
pages = "623--629",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors

AU - Perez, Eduardo A.

AU - Livingstone, Alan S.

AU - Franceschi, Dido

AU - Rocha-Lima, Caio

AU - Lee, David J.

AU - Hodgson, Nicole

AU - Jorda, Merce

AU - Koniaris, Leonidas G.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - BACKGROUND: Gastrointestinal stromal tumors (GISTs) have been recognized as the most common mesenchymal tumors of the gastrointestinal tract. The most effective treatment for unresectable tumors is imatinib mesylate, based on two phase II trials. Because no phase III clinical trial has been undertaken, we sought to determine both current population-based incidence and whether improved outcomes noted in both individual centers and clinical trials have also been observed in a large prospective cancer registry earlier and after the introduction of imatinib. STUDY DESIGN: The 13-center cumulative tumor registry (April 2005 release) from the Surveillance, Epidemiology, and End Results (SEER) database was queried from 1992 to 2002 to determine incidence and associated outcomes for patients diagnosed with GIST. Confirmations of incidence trends using the incident Florida Cancer Data System (FCDS, 2005 release) were also determined. RESULTS: A 25-fold age-adjusted increase in incidence of GIST, from 0.028 per 100,000 in 1992 to 0.688 per 100,000 in 2002, was observed. This increase is mostly because smooth-muscle tumors have been reclassified as GISTs, but it also represents a 50% increase in population- and age-adjusted gastrointestinal mesenchymal tumor diagnosis since 1992. Despite rising GIST incidence rates, there has been a marked improvement in survival since 2000, coinciding with the introduction of the tyrosine kinase inhibitor imatinib into clinical practice. CONCLUSIONS: The diagnosis of GIST has dramatically increased since 1992. Survivals have greatly improved since 2000, when imatinib mesylate was FDA approved.

AB - BACKGROUND: Gastrointestinal stromal tumors (GISTs) have been recognized as the most common mesenchymal tumors of the gastrointestinal tract. The most effective treatment for unresectable tumors is imatinib mesylate, based on two phase II trials. Because no phase III clinical trial has been undertaken, we sought to determine both current population-based incidence and whether improved outcomes noted in both individual centers and clinical trials have also been observed in a large prospective cancer registry earlier and after the introduction of imatinib. STUDY DESIGN: The 13-center cumulative tumor registry (April 2005 release) from the Surveillance, Epidemiology, and End Results (SEER) database was queried from 1992 to 2002 to determine incidence and associated outcomes for patients diagnosed with GIST. Confirmations of incidence trends using the incident Florida Cancer Data System (FCDS, 2005 release) were also determined. RESULTS: A 25-fold age-adjusted increase in incidence of GIST, from 0.028 per 100,000 in 1992 to 0.688 per 100,000 in 2002, was observed. This increase is mostly because smooth-muscle tumors have been reclassified as GISTs, but it also represents a 50% increase in population- and age-adjusted gastrointestinal mesenchymal tumor diagnosis since 1992. Despite rising GIST incidence rates, there has been a marked improvement in survival since 2000, coinciding with the introduction of the tyrosine kinase inhibitor imatinib into clinical practice. CONCLUSIONS: The diagnosis of GIST has dramatically increased since 1992. Survivals have greatly improved since 2000, when imatinib mesylate was FDA approved.

UR - http://www.scopus.com/inward/record.url?scp=33645291186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645291186&partnerID=8YFLogxK

U2 - 10.1016/j.jamcollsurg.2006.01.002

DO - 10.1016/j.jamcollsurg.2006.01.002

M3 - Article

C2 - 16571433

AN - SCOPUS:33645291186

VL - 202

SP - 623

EP - 629

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 4

ER -